• Home
• Patronate
• International Advisory Board
• Meetings
• Publications
• Aims
• Contact

Meetings

Neurodevelopmental Liabilities in Brain Disease States

Mojácar (Almería)

October 18 - 22 2001

The content of this congress, together with other contributions on the topic, are collected in vol. 6 of the series "Strategies for studying brain disorders".

PROGRAMME

1. S1. NEUROBIOLOGICAL CONDITIONS ASSOCIATED WITH DISORDER VULNERABILITY
   • David de Wied, The Netherlands. Remembering Bela: a small commemoration of the Bohusian contributions to Behavioural Neuroscience.
   • Barbara Lipska, USA. A Neurodevelopmental Model of Schizophrenia: Neonatal Disconnection of The Hippocampus.
   • Michel Le Moal, France. Neurodevelopmental factors associated with potential for substance abuse and affective disorders.
   • David de Wied, The Netherlands. Role of neuropeptides in the etiology of psychiatric disorders.
   • Rolf Ekman, Sweden. Neurodevelopmental Influence on the Immune System Reflecting Brain Pathology.
   • Herman Van Praag, The Netherlands. Anxiety/Aggression-driven Depression.About the Role of Serotonin and Cortisol in the Pathophysiology of Certain Types of Depression.
   • Jerzy Vetulani, Poland. A possible physiological role for cerebral tetrahydroisoquinolines.
2. S2. VULNERABILITY FOR SCHIZOPHRENIA: STRUCTURAL, NEUROHUMORAL AND INCIDENTAL FACTORS
   • Robin Murray, UK. Schizophrenia and Bipolar Disorder: Similar Pathogenic Mechanisms but differences in Neurodevelopment.
   • Richard Beninger, Canada. Neonatal Exposure to MK-801: Behavioral Effects in Juvenile and Adult Rats.
   • Vicente Molina, Spain. Functional and Structural Neuroimaging Studies on Recent-Onset Schizophrenia.
   • José Borrell, Spain. Neurovulnerability to immune system alterations during development.
   • Mark Geyer, USA. Developmental markers of psychiatric disorders as identified by sensory gating.
3. S3. NEURODEVELOPMENTAL LIABILITIES INFLUENCING AFFECTIVE STATES
   • George Robert DeLong, USA. Fluoxetine Response in Young Children with Autistic Spectrum Disorders.
   • Francisco Artigas, Spain. Control of Aminergic Systems by the Medial Prefrontal Cortex. Potential Role in the Etiology of PTSD and Depressive Disorders.
   • Feng Zhou, USA. Deviations in Brain Serotonergic Development.
   • Pedro L. Delgado, USA. Serotonergic neuronal systems and development in health and disease.
   • Seymur Levine, USA. Environmental factors influencing the ontogeny of the HPA-axis.
   • Luis Miguel García Segura, Spain. Brain vulnerability and gonadal hormones.
   • Athina Markou, USA. Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across diagnostic categories.
4. S4. THE LIABILITY POTENTIAL OF ABUSE SUBSTANCES
   • Claudio A. Naranjo, Canada. Central Serotonin Dysfunction and Alcohol Dependence.
   • Consuelo Guerri, Spain. Mechanisms Involved in Central Nervous System Dysfunctions Induced by Prenatal Alcohol Exposure.
   • Jose Antonio Ramos, Spain. Exposure to cannabinoids in the development of endogenous cannabinoid system.
   • John Olney, USA. Glutamate and GABA receptor dysfunction in Fetal Alcohol Syndrome.
   • Lars Oreland, Sweden. Risk factors for the neurohumoral alterations underlying personality disturbances.
   • John Harvey, USA. Abnormalities In The Dopamine D1/P38 Mapk/Creb Molecular Cascade Produced By Prenatal Exposure To Cocaine: Behavioral Correlates.
5. S5. RISK FACTORS AFFECTING VULNERABILITY FOR MOVEMENT
   • Moussa Youdim, Israel. cDNA Micrarray of Early and Late Gene Expressions in Neurodevelopment of MPTP and 6-Hydroxydopamine Induced Dopaminergic Neurodegeneration.
   • Trevor Archer, Sweden. Postnatal Iron Exposure-Induced Neurofunctional Deficits: Experimental Parkinsonism?.
   • Justo García de Yébenes, Spain. Neurotrophic Factors and Parkinson's Disease.
   • Catherine Bennett, USA. Parkinson´s Disease Pathology: Role of a-Synuclein in normal and disease states.
   • Antonio Gil Nagel, Spain. Neurodevelopmental liabilities in epilepsy.
   • Manfred Gerlach, Germany. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson´s Disease.
6. S6. THE BALANCE SHEET OF NEURODEVELOPMENTAL LIABILITY
   • Bruce Trapp, USA. Axonal Loss in Multiple Sclerosis.
   • Lourdes Fañanás, Spain. Genetic Variation and the Complex Phenotype of Mental Disorders.
   • Pierre Sokoloff, France. Role of BDNF in Neurodevelopmental and Pharmacological Adaptive Changes of Dopamine Neurotransmission.
   • Peter Riederer, Germany. Developmental factors leading to movement disorders, in particular Parkinson's Disease.
   • Iván Izquierdo, Brazil. Memory Retrieval and its Lasting Consequences.
   • Richard M. Kostrzewa, USA. The destructive propensities of perinatal neurotoxins on brain development and function.

STRATEGIES FOR STUDYING BRAIN DISORDERS

© 2009 Fundación Cerebro y Mente All rights reserved